RTSA has the potential to achieve better functional outcomes compared with other treatment strategies. 9 However, RTSA has been associated with higher complication and reoperation rates as well as greater costs. 8, 10 Previously, cost analyses have been conducted for both rotator cuff repairs and arthroplasty for glenohumeral osteoarthritis. 11, 12 The cost effectiveness of interventions for massive irreparable rotator cuff tears has never been evaluated, and no head-to-head comparative effectiveness trials have been reported in the literature.
The current authors hypothesize that RTSA is a cost-effective strategy for the treatment of massive irreparable rotator cuff tears in elderly patients given a willingness-to-pay (WTP) threshold of $50,000. This threshold is a cost-effectiveness analysis standard that has gained wide acceptance for orthopedic surgery cost-utility analysis. [13] [14] [15] [16] The primary aims of this study were: (1) to determine the relative cost effectiveness of 4 treatment strategies for massive irreparable rotator cuff tears using a decision analytic model and (2) to perform sensitivity analyses of the probabilities, utilities, and costs inputs to account for model accuracy and precision.
Materials and Methods

Decision Model Overview
The decision analytic model, inputs, and supporting analysis were conducted according to recommendations by the US Panel on Cost-Effectiveness in Health and Medicine. [14] [15] [16] The base case scenario was a cohort of 70-year-old female patients with shoulder pain, 90° of active forward elevation of the shoulder, and a massive irreparable rotator cuff tear on advanced imaging. Ninety degrees of active forward elevation was chosen because it is the threshold to achieve overhead motion, and less than 90° of forward elevation defines pseudoparalysis of the shoulder. The treatment strategies of PT, AD-BT, HA, and RTSA for massive irreparable rotator cuff tears were analyzed using a Markov decision analytic model (TreeAge Software, Williamstown, Massachusetts) with cycle length of 1 year. Inputs for cost were based on Centers for Medicare & Medicaid Services (CMS) reimbursement data. All other inputs were derived from the literature when available. An annual discount rate of 3% was used for both costs and utilities to reflect their present value, and the background death probability was determined from Centers for Disease Control and Prevention values.
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Markov Decision Analytic Model
For the Markov decision analytic model, PT, AD-BT, HA, and RTSA were used as treatment arms for massive irreparable rotator cuff tears (Figure 1) . Patients enter an initial postprocedure state for 1 year in which they have experienced perioperative death, no complications, or morbidities associated with their primary procedure. For patients who have experienced morbidities, they will choose among 3 options:
1. Not pursue any other treatment options (patients who first chose PT, AD-BT, HA, or RTSA).
2. Undergo reoperation (patients who first chose HA or RTSA).
3. Convert to an RTSA (patients who first chose PT, AD-BT, or HA)
After this initial postprocedure state, patients enter a Markov model cycled on a yearly basis with a background probability of death from nonperioperative causes, a return to baseline clinical function, implant failure, or no clinical change. Given the baseline scenario consisting of an elderly population, patients underwent at most 2 reoperations. The approach taken with the development of this Markov decision analytic model is consistent with , and reverse total shoulder arthroplasty (RTSA) also have respective subdecision trees similar to the one shown for hemiarthroplasty (HA). Each decision branch has associated transition probabilities, health state utilities, and costs, and it is assumed that all procedure-related decisions take place within 1 year. The Markov model (designated by the M) was run on an annual cycle from ages 70 through 99. Although the Markov model accounts for time-dependent decrease in health state utility toward baseline or natural death, no additional procedure costs were included.
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comparable cost-effectiveness studies in the field.
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Model Parameters
Probabilities and Utilities. Probabilities for complications, perioperative death, conversion procedures, and reoperations were based on a comprehensive literature review of relevant meta-analyses and primary outcome studies ( Table 1) . Transition probabilities between procedures and the Markov model health states, as well as health state utilities inputs expressed in QALY, were derived from the literature ( Table 1) . Inputs were only approximated from comparable literature values or estimated based on expert opinion (E.V.C.) when not available directly in the literature. For HA reoperations with morbidities, no direct data for massive irreparable rotator cuff tear patients were identified, so a 3 times higher complications rate relative to primary HA was assumed based on the RTSA difference noted in the literature. 18, 19 Patients who convert to RTSA was approximated based on PT to RTSA conversion rates. 20 Health state utilities are critical for cost-effectiveness analyses as they capture clinical outcomes in standardized, cross-study comparable QALY. Utilities ranged from 0 to 1, with 0 corresponding to death and 1 corresponding to complete health. Utility of patients' health states were derived by scaling shoulder scoring systems, such as the Disabilities of the Arm, Shoulder, and Hand Questionnaire (DASH), Shoulder Pain and Disability Index (SPADI), American Shoulder and Elbow Surgeons (ASES) Society standardized shoulder assessment form, and Constant-Murley Score, to dimensions of the 36-Item Short Form Health Survey (SF-36) as described by Angst et al. 21 All results were adjusted relative to a Constant-Murley baseline score of 30.
Sensitivity analysis was used to address the conflicting results on whether shoulder scores correlated with SF-36 scores. [21] [22] [23] Given sparse data on the im- Copyright © SLACK inCorporAted n Feature Article pact of complications on health state disutility, the disutility in a primary procedure was approximated to be 0.05, and in a secondary procedure, it was approximated to be 0.07. The 0.07 disutility was based on a difference between HA and reoperation HA as noted in the literature. 8, [24] [25] [26] Although data existed for HA and RTSA implant failure, return to baseline data were only available for RTSA; for the other 3 treatment options, rates of return to baseline were approximated based on the RTSA rates. 18, 27, 28 Specifically, HA was estimated to have the same return to baseline rates as RTSA in years 1 to 6 and years 7+ time frames (0.02 and 0.08, respectively) to approximate similar long-term decrease in clinical effectiveness. For PT and AD-BT, a rate was estimated equivalent to an average of those 2 time frames (0.05), which approximates a gradual, steady decrease in function over time.
Costs. Costs were determined from average Medicare reimbursement rates from 2011 ( Tables 2-3) . Medicare reimbursement data reflect a national average that limits the impact of regional, health care system, and practice-specific factors on costs. Medicare serves as the largest payor in the United States for elderly patients and plays a role in the market as a "price-setting" entity. For outpatient PT and AD-BT, Current Procedural Terminology (CPT) codes were used to capture facility reimbursements and professional fees. Key primary and secondary HA and RTSA costs were captured using Medicare acute inpatient Prospective Payment System (PPS) reimbursements per Medicare Severity Diagnosis Related Group (MS-DRG) codes, and both surgeon and anesthesia professional fees per CPT codes. Additional categories were included for cost of laboratory tests and shared procedure medications. Cost of HA and RTSA implants was approximated from industry sources as no other published cost sources were available.
Cost-effectiveness Analysis
The Markov decision analytic model was run for the base case scenario using inputs to determine the most cost-effective treatment option. For each treatment approach, both the present value of the cost in dollars and the health state utility 
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Copyright © SLACK inCorporAted n Feature Article in QALY-accounting for the quantity and quality of life-were calculated. Cost effectiveness among the treatment options was first determined by plotting all treatments on the cost-effectiveness plane (Y-axis QALY, X-axis $US) to get a visual representation of the cost-efficiency frontier. Treatment strategies were considered strictly dominated if there was another treatment strategy that was both more effective and less costly. They were considered extended dominated if a more costly treatment option had a lower cost-effectiveness ratio or if a linear combination of 2 options on the cost-efficiency frontier strictly dominated a treatment option. The primary quantitative result calculated, the incremental cost-effectiveness ratio (ICER), defined as (Cost Treatment A -Cost TreatmentB )/(QALY TreatmentA -QALY TreatmentB ), was determined between each sequential treatment option on the cost-efficiency frontier. An ICER less than the cost-effectiveness analysis standard WTP threshold of $50,000 per QALY gained (a standard accepted in the orthopedic surgery cost-utility analysis community) was considered cost effective as it provided a sufficient incremental gain in health utility at a low enough incremental cost to the health care system. [13] [14] [15] [16] The most cost-effective treatment option was the highest utility treatment approach that also had an ICER less than WTP of $50,000/QALY. If no ICER met that cutoff, then the treatment option with lowest cost and utility was the most cost-effective option.
Sensitivity Analysis
To account for input variables in the study that were not derived from the literature, sensitivity analyses were used to evaluate the relative impact of changes to the variables within reasonable ranges. For most variables, ±20% base case values was chosen as the range, although ranges were adjusted to be larger or smaller in cases where the uncertainty was greater or less, respectively. Tables 1-2 show the sensitivity ranges that were used for all inputs. Sensitivity analyses allowed for the impact of concurrently changing 1 or more variables to be quantified on the overall cost-effectiveness result. If the preferred, most cost-effective treatment option changed when a variable was varied across its sensitivity range, then the result was sensitive to that variable. For all probabilities, health state utilities, and costs, ICER tornado plots and 2-way sensitivity analyses were conducted.
results
The clinical outcomes of the four interventions are different ( Table 1 ). Higher complication rates correlated with increased invasiveness (0.0 for PT, 0.04 for HA, 0.09 for AD-BT, and 0.13 for RTSA primary procedures). The complication rates for reoperation HA increased to 0.10, and for either conversion of HA to RTSA or reoperation RTSA, the complication rate was 0.33. Perioperative death rates were 0.0 for PT and AD-BT, and 0.01 for HA and RTSA. The conversion rate to RTSA was similar for PT, AD-BT, and HA at 0.18, 0.20, and 0.18, respectively. For HA patients with complications, 0.67 decided on a reoperation HA, and the remaining 0.15 chose to stay with their primary HA procedure. For RTSA patients with complications, 0.69 chose a reoperation RTSA and 0.31 chose to stay with their primary RTSA procedure. Primary procedure health state utilities were 0.70 for PT, 0.64 for AD-BT, 0.70 for HA, and 0.75 for RTSA, with 0.05 or 0.07 disutility for complications and conversion or reoperation secondary procedures. The outcomes translated into 6.69 QALY for AD-BT, with PT increasing QALY to 7.04, HA to 7.35, and RTSA to 7.69.
The summary costs for each intervention, inclusive of inpatient facility or outpatient ambulatory surgical care fees, as well as surgeon, anesthesia, laboratory, drug, and implant fees as applicable, are shown in Combining QALY and costs, PT was found to cost $4719 per QALY gained relative to AD-BT, and RTSA was found to cost $25,552 per QALY gained relative to PT (Figure 2 and Table 4 ). HA was extended dominated by a linear combination of PT and RTSA. At a WTP threshold of $50,000/QALY, sensitivity analyses showed that the most cost-effective intervention was PT at a health utility of approximately 0.75 or greater (QALY 7.35), AD-BT at a health utility of approximately 0.73 or greater (QALY 7.35), and HA (QALY 7.35 at the cost of $17,414) with an RTSA health utility approximately 0.72 or less (QALY 7.48) or RTSA probability of no complications 0.83 or less (QALY 7.48 at the cost of $23,830). Sensitivity of the cost-effectiveness result to the above variables was first identified using PT to RTSA and AD-BT to PT ICER tornado plots (Figures 3-4) . Two-way sensitivity analyses demonstrate the base case relative to threshold values at which the preferred, most cost-effective intervention changes.
discussion
Recently, RTSA has become an increasingly popular treatment for patients with massive irreparable rotator cuff tears. 29 The results of the currently described model supports this growing trend toward RTSA by establishing it as the most cost-effective treatment option from a financial perspective. Although RTSA is substantially more expensive than PT and AD-BT, the incremental cost is worth the significant clinical outcomes gains that are achieved. The extra money spent on RTSA is worth the additional cost from a societal perspective as captured by a WTP of $50,000/QALY. Clinically, this is consistent with the patient population being treated: elderly patients with painful, massive irreparable rotator cuff tears at baseline. Both HA and RTSA should be considered in patients who desire gains in functionality, whereas PT and AD-BT may be cost-efficient treatment options for elderly patients with lower functionality demands who are desiring pain relief as these interventions still offer clinical benefits at lower costs and risks associated with surgery.
Although PT and AD-BT might appear as the most cost-effective treatment option within the uncertainty ranges analyzed, those results need to be considered within their clinical context. It is unlikely that the average individual patient has the same clinical outcome and thus equivalent health utility at 0.75, whether they choose PT vs RTSA. Likewise, an increase in health utility of 0.09 from 0.64 to 0.73 for AD-BT to a level nearly as high as RTSA's base case value of 0.75 also is incongruent with clinical experience. However, the small changes in RTSA health utility (0.75 to ≤0.72) or RTSA probability of no complications (0.86 to ≤0.83) needed for a change to HA as the most cost-effective option are within the uncertainty for those model parameters.
There are several weaknesses to this cost-effectiveness study. Despite a rigorous process for identifying inputs and building the Markov decision analytic model, the study was constrained by the available literature and the limitations of the data. Few studies specifically targeted this patient population, and inputs were extracted from subsets of data or accepted for use despite partial demographic fits. Both HA and RTSA are technically demanding procedures, and provider variations, such as surgeon experience, case volume, or type of practice, could not be accounted for patientspecific factors, namely comorbidities and socioeconomic factors, which also could impact clinical outcomes. Lastly, although Medicare reimbursement data are the standard source for cost data studies, these data capture what is paid out and not the true costs to health care systems, providers, and patients. Models have inherent weaknesses, but they can be instrumental in answering clinical questions that cannot be explored through traditional clinical studies. 
conclusion
RTSA is the preferred and most costeffective treatment option for elderly patients with massive irreparable rotator cuff tears. For patients seeking pain relief without functional gains, AD-BT can be considered as a cost-effective and less expensive alternative. The cost-effectiveness analysis approach can help guide clinical practice by individual surgeons as well as the policies of health care systems and insurers. Further study is warranted to evaluate clinical correlation between functional gains and modeling-based analyses.
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